The Latest Cardiac and Vascular News
Closed $26.5 Million with a Public Offering and Registered Direct Offering to Enable Company to Execute on Upcoming Clinical, Regulatory and Commercial Milestones and Extend Cash Runway into Late 2024 Strategic Focus on Becoming the Global Leader in Ambulatory Vectorcardiography, the Highest Resolution ECG Monitoring Platform Management to Host Webcast […]
HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for the treatment of atrial fibrillation, today announced financial results for the first quarter ended March 31, 2023. Business Updates Announced the appointment of Gansevoort “Gan” Dunnington, MD, as Chief […]
The company confirms its sales target of €10-13 million for 2023 PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of Aeson®, the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure, informs its shareholders that the Combined General […]
2023 Q1 highlights: Revenue was $18.2 million, an increase of 30% compared to the corresponding period of 2022 Net income was $5.0 million, an increase of 48% compared to the corresponding period of 2022 Cash, cash equivalents and short-term investments of $43.0 million SANTA CLARA, Calif., May 10, 2023 /PRNewswire/ — Semler Scientific, Inc. (Nasdaq: SMLR), […]
DENVER, May 10, 2023 /PRNewswire/ — ViewRay, Inc. (Nasdaq: VRAY) (the “Company”) today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023 Highlights Total revenue for the first quarter 2023 was approximately $22.5 million, primarily from three revenue units, compared to approximately $18.9 million, primarily from three revenue units, in the […]
SUNNYVALE, Calif., May 10, 2023 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the first quarter of 2023 and filed its quarterly report on Form 10-Q for the three months ended March 31, […]
– All Four Business Segments Achieved Growth Led by Strong SimpliDerm and CanGaroo Sales – SILVER SPRING, Md., May 10, 2023 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, […]
Announced launch and commercial availability of FUROSCIX® on February 20th Generated net FUROSCIX revenue of $2.1 million Ended Q1 2023 with cash, cash equivalents and short-term investments of $116.1 million Company to host investor conference call and webcast today, Wednesday, May 10, at 4:30pm ET BURLINGTON, Mass., May 10, 2023 (GLOBE […]
TN-201 Received Fast Track Designation from the FDA Dosing Complete in Phase 1 Clinical Trial of TN-301; Data Expected in Second Half 2023 Renowned Researchers Drs. Christine Seidman and Alex Marson Join Scientific Advisory Board Announces Formation of Technical Advisory Board with Deep Expertise in Gene Therapy Manufacturing SOUTH SAN […]
– NDA submission for etripamil in patients with PSVT currently on track for 3Q23 – Company to host virtual KOL event focused on etripamil for the potential treatment of AFib-RVR on Monday, May 22, 2023 – Topline data from Phase 2 ReVeRA study evaluating etripamil in patients with AFib-RVR expected in 2H, 2023 – […]
